| 1 |
Kotton CN. CMV: Prevention, diagnosis and therapy[J]. Am J Transplant, 2013, 13 Suppl 3：24-40.
|
| 2 |
Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation[J]. JAMA, 1989, 261(24)：3607-3609.
|
| 3 |
巨春蓉，练巧燕，蔡宇航，等. 胸腔脏器移植受者巨细胞病毒感染情况及预后分析[J/CD]. 中华移植杂志：电子版，2021, 15(4)：193-198.
|
| 4 |
巨春蓉，郝建清，何建行，等. 移植受者耐药巨细胞病毒感染的诊治[J]. 中华器官移植杂志，2023, 44(3)：146-151.
|
| 5 |
巨春蓉，韦兵，练巧燕，等. 实体器官移植术后巨细胞病毒肺炎的防治策略—ATS巨细胞病毒肺炎的诊治指南解读[J]. 器官移植，2019, 10(1)：88-90.
|
| 6 |
Yong MK, Shigle TL, Kim YJ, et al. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation[J]. Transplant Cell Ther, 2021, 27(12)：957-967.
|
| 7 |
Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation[J]. Transplantation, 2018, 102(6)：900-931.
|
| 8 |
Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients[J]. J Infect Dis, 2005, 192(7)：1154-1157.
|
| 9 |
Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2007, 7(9)：2106-2113.
|
| 10 |
Fisher CE, Knudsen JL, Lease ED, et al. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients[J]. Clin Infect Dis, 2017, 65(1)：57-63.
|
| 11 |
Hofmann E, Sidler D, Dahdal S, et al. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature[J]. Transpl Infect Dis, 2021, 23(3)：e13515.
|
| 12 |
Van Leer Buter CC, de Voogd DWK, Blokzijl H, et al. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands[J]. J Antimicrob Chemother, 2019, 74(8)：2370-2376.
|
| 13 |
Brar S, Berry R, Raval AD, et al. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia[J]. Clin Transplant, 2022, 36(4)：e14583.
|
| 14 |
Kotton CN, Kamar N. New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant/refractory disease[J]. Infect Dis Ther, 2023, 12(2)：333-342.
|
| 15 |
Khawaja F, Spallone A, Kotton CN, et al. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium[J]. Clin Microbiol Infect, 2023, 29(1)：44-50.
|
| 16 |
Ju C, Wang X, Xu X, et al. Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study[J]. BMC Infect Dis, 2022, 22(1)：872.
|
| 17 |
Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir[J]. Antivir Ther, 2009, 14(5)：697-704.
|
| 18 |
Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients[J]. J Infect Dis, 2002, 186(6)：760-768.
|
| 19 |
Ambrose T, Sharkey LM, Louis-Auguste J, et al. Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation[J]. Transplant Proc, 2016, 48(2)：492-496.
|
| 20 |
Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation[J]. Clin Microbiol Rev, 2020, 34(1)：e00043-19.
|
| 21 |
Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients[J]. Transplant Proc, 2011, 43(6)：2145-2148.
|
| 22 |
Al-Badr AA, Ajarim TDS. Ganciclovir[J]. Profiles Drug Subst Excip Relat Methodol, 2018, 43：1-208.
|
| 23 |
El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients[J]. Blood, 2016, 128(23)：2624-2636.
|
| 24 |
Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus[J]. Clin Microbiol Rev, 2010, 23(4)：689-712.
|
| 25 |
Kleiboeker SB. Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients[J]. Antiviral Res, 2023, 215：105623.
|
| 26 |
Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group[J]. Antimicrob Agents Chemother, 1998, 42(9)：2240-2244.
|
| 27 |
Görzer I, Guelly C, Trajanoski S, et al. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time[J]. J Virol, 2010, 84(14)：7195-7203.
|
| 28 |
Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing[J]. J Clin Microbiol, 2013, 51(11)：3700-3710.
|
| 29 |
Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing[J]. Antimicrob Agents Chemother, 2014, 58(8)：4697-4702.
|
| 30 |
Chou S． Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance[J]. Antiviral Res, 2020, 176：104711.
|
| 31 |
Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials[J]. Clin J Am Soc Nephrol, 2017, 12(8)：1321-1336.
|
| 32 |
Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study[J]. Am J Transplant, 2009, 9(8)：1816-1825.
|
| 33 |
Hayes M, Boge CLK, Sharova A, et al. Antiviral toxicities in pediatric solid organ transplant recipients[J]. Am J Transplant, 2022, 22(12)：3012-3020.
|
| 34 |
Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection[J]. Transplantation, 2016, 100(10)：e74-e80.
|
| 35 |
Mehta Steinke SA, Alfares M, Valsamakis A, et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection[J]. Transpl Infect Dis, 2021, 23(3)：e13521.
|
| 36 |
Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication[J]. Antimicrob Agents Chemother, 2002, 46(8)：2373-2380.
|
| 37 |
Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects[J]. Antimicrob Agents Chemother, 2003, 47(4)：1334-1342.
|
| 38 |
Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, Phase 2 study[J]. Clin Infect Dis, 2019, 68(8)：1255-1264.
|
| 39 |
Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation[J]. N Engl J Med, 2019, 381(12)：1136-1147.
|
| 40 |
Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial[J]. Clin Infect Dis, 2022, 75(4)：690-701.
|
| 41 |
Bassel M, Romanus D, Bo T, et al. Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: data at 52 weeks post-maribavir treatment initiation[J]. Antivir Ther, 2023, 28(5)：13596535231195431.
|
| 42 |
Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir[J]. J Infect Dis, 2010, 202(1)：104-108.
|
| 43 |
Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain Ⅱ mutant[J]. J Virol, 2008, 82(1)：246-253.
|
| 44 |
Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era[J]. Clin Infect Dis, 2021, 73(8)：1346-1354.
|
| 45 |
Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J]. Am J Transplant, 2011, 11(5)：1079-1084.
|
| 46 |
Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients[J]. Transplantation, 2020, 104(2)：404-409.
|
| 47 |
Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis[J]. Antimicrob Agents Chemother, 2019, 63(3)：e02337-18.
|
| 48 |
Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections[J]. Future Microbiol, 2020, 15：389-400.
|
| 49 |
Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled Phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(2)：369-381.
|
| 50 |
Vial R, Zandotti C, Alain S, et al. Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection[J]. Case Rep Transplant, 2017：3624146.
|
| 51 |
Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients[J]. Pharmacotherapy, 2010, 30(6)：554-561.
|
| 52 |
Wiening V, Schmidt T, Dahmen M, et al. Case report: management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression, and induction of CMV-specific cellular immunity[J]. Front Immunol, 2020, 11：623178.
|
| 53 |
Pearston AP, Ingemi AI, Ripley K, et al. Successful treatment of UL97 mutation ganciclovir-resistant cytomegalovirus viremia in a renal transplant recipient with letermovir and adjunct hyperimmune cytomegalovirus immunoglobulin: a case report[J]. Transplant Proc, 2021, 53(4)：1284-1287.
|
| 54 |
Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis[J]. J Clin Oncol, 2009, 27(5)：770-781.
|
| 55 |
Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones[J]. Science, 1992, 257(5067)：238-241.
|
| 56 |
Ke P, Bao X, Zhou J, et al. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation[J]. Hematology, 2020, 25(1)：43-47.
|
| 57 |
Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label Phase I clinical trial[J]. Clin Infect Dis, 2019, 68(4)：632-640.
|
| 58 |
Holmes-Liew CL, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation[J]. Clin Transl Immunology, 2015, 4(3)：e35.
|
| 59 |
Miele M, Gallo A, Di Bella M, et al. Successful use of heterologous CMV-reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome[J]. Microorganisms, 2021, 9(4)：684.
|
| 60 |
Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient[J]. Am J Transplant, 2015, 15(3)：827-832.
|